1. Каталог >
  2. Клеточные линии, штаммы, среды >
  3. Клеточная биология >
  4. Антитела >

Anti-EphA1: Mouse EphA1 Antibody


BACKGROUND Eph family of receptor tyrosine kinases consists of at least 14 distinct receptors and has eight membrane-bound ligands, known as the ephrins.  This is the largest family of receptor tyrosine kinases.  Eph proteins are divided into two subfamilies: the EphA receptors (A1-A8) that bind glycosyl phosphatidylinositol (GPI)-linked ephrin-A ligands (A1-A5), and the EphB receptors (B1-B6) that bind transmembrane ephrin-B ligands (B1-B3). The only known crosstalk between the A and B subfamilies occurs with the EphA4 receptor, which can bind ephrins-B2 and -B3 as well as the entire A subclass. There is a great deal of redundancy of receptor-ligand binding specificity within each subfamily, although binding affinities vary.1,2 Both GPI-anchoredephrinA and transmembrane ephrinB ligands interact with the Nterminal globular domain (Glob) of Eph receptors. The Eph receptors become phosphorylated at specific tyrosine residues in the cytoplasmic domain following ligand binding. Phosphorylated motifs serve as sites of interaction with certain cytoplasmic signaling proteins to mediate downstream signaling. In addition, through their C terminus the Eph receptors associate with PDZ (postsynaptic density protein, disc large, zona occludens) domain-containing proteins. Moreover, Eph receptor contact induces tyrosine phosphorylation of the cytoplasmic domain of ephrinB proteins via an SRC-family kinase (SFK), which mediating the reverse signaling.  One of the unique features of Eph/ephrin signaling is the fact that both receptors and ligands are competent to transduce a signaling cascade upon interaction. Eph-activated signaling is termed forward, and ephrin-activated signaling is termed reverse. Another level of complexity stems from the fact that interactions between Eph receptors and ephrins can happen in trans (between two opposing cells) or in cis (within the same cell). It is commonly assumed that trans interactions are activating while cis interactions are inhibiting.3 Eph-Ephrin signaling functions in a variety biological processes including diverse assegmentation of the somites and rhombomeres, the formation of blood vessels, Axon guidance and fasciculation, migration of the neural crest and metastasis of transformed cells etc.

EphA1 was the first member of the Eph family to be identified and is expressed mainly in epithelial tissues. This receptor is implicated in tumorigenicity. Low expression levels of EphA1 in malignant tumors have been reported. In breast carcinoma cells, downregulated EphA1 expression is associated with invasive behavior of the cells, which is accompanied by dysregulation of other Eph-ephrin family members. It was demonstrated that EphA1 regulates cell morphology and motility through the ILK-RhoA-ROCK pathway.4
 
REFERENCES  
1. Brantley-Sieders, D.M. & Chen, J.: Angiogenesis. 7:17, 2004
2. Murai, K.K. & Pasquale, E.B.: J. Cell Sci. 116:2823, 2003
3. Arvanitis, D. & Davy, A.: Genes & Dev. 22:416, 2008
4. Yamazaki, T. et al: J. Cell Sci. 122:243-55, 2009
 
Products are for research use only. They are not intended for human, animal, or diagnostic applications.

Параметры

Cat.No.:
CP10079
Antigen:
Purified recombinant human EphA1 fragments expressed in E. coli.
Isotype:
Mouse IgG1
Species & predicted
species cross-
reactivity ( ):
Human
Applications &
Suggested starting
dilutions:*
WB                  1:1000
IP                    n/d
IHC                  1:200
ICC                  n/d
FACS               n/d
Predicted Molecular
Weight of protein:
108 kDa
Specificity/Sensitivity:
Detects endogenous EphA1 proteins without cross-reactivity with other family members.
Storage:
Store at -20°C, 4°C for frequent use. Avoid repeated freeze-thaw cycles.

*Optimal working dilutions must be determined by end user.



Документы



НазваниеКодЦена
Mouse EphA1 Antibody CP10079 38559.35 руб.




Информация представлена исключительно в ознакомительных целях и ни при каких условиях не является публичной офертой